How Ph.D. was paid
$7.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Roger A. Jeffs, Ph.D.Chief Executive Officer | $824,000 | $25,000 | $5,590,992 | $1,254,400 | $18,344 | $7,712,736 |
| Michael KasetaChief Financial Officer and Chief Operating Officer | $592,250 | $25,000 | $2,749,991 | $772,800 | $16,022 | $4,156,063 |
| Russell SchundlerGeneral Counsel and Secretary | $540,750 | $25,000 | $2,499,998 | $588,000 | $17,347 | $3,671,095 |
| Rajeev Saggar, M.D.Chief Medical Officer | $539,349 | $25,000 | $1,749,996 | $586,477 | $16,022 | $2,916,844 |
| Scott MoomawChief Commercial Officer | $449,904 | $25,000 | $1,699,993 | $489,216 | $16,841 | $2,680,954 |
What changed and why
- $7.7MCEO total compensation increased to $7,712,736 in fiscal 2025.
- 97.1%Stockholders approved the prior say-on-pay proposal with 97.1% support.
- Company achieved profitability and successful commercial launch of YUTREPIA.
- 200%Non-equity incentive payouts reflected 200% achievement of corporate goals.
- $25,000Special cash bonuses of $25,000 were paid for the first commercial sale.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.